IMDNA provides scientific, technical, manufacturing, and non-regulatory support for lot-specific quality control and internal release testing of molecular research reagents, qPCR/RT-qPCR assay components, primer/probe mixes, master mixes, controls, buffers, extraction reagents, immunoassay reagents, research kits, and related laboratory products within IMDNA's technical capabilities. Support can include lot identity and traceability review, concentration and formulation checks, fill-volume verification, functional qPCR/RT-qPCR testing, control performance, multiplex balance, lot-to-lot comparison, stability-related checks, deviation review, technical documentation, and internal lot-disposition support.
Lot-specific QC should answer a focused manufacturing question: does this lot conform to the predefined product specification and perform consistently with the technical characteristics established for the product? For molecular reagents, physical conformance alone may not be enough. A primer/probe mix can have the correct fill volume yet show altered amplification behavior; a control can be present at the intended concentration yet fail functional expectations; and a multiplex reagent can pass individual-component checks while showing target competition in the complete assay. IMDNA therefore combines traceability, product-specific measurements, and functional testing where scientifically appropriate.
FDA IVD labeling requirements use lot/control numbers to preserve traceability to production history, including suitable identification of components intended to function together as a system. CLSI EP26 separately addresses how a user laboratory can evaluate a new reagent lot against the lot already in use. These concepts support two complementary quality questions: the manufacturer evaluates whether a lot meets its product specifications, while a receiving laboratory may independently assess whether a new lot behaves acceptably in its own testing environment.
Confirm the correct product, formulation, component configuration, manufacturing batch, and relevant raw-material lots.
Evaluate defined measurable attributes such as concentration, pH, volume, appearance, composition, signal, activity, or other product-specific criteria.
Use the actual assay or an appropriate functional test to determine whether the manufactured reagent performs as intended.
Compare a candidate lot with a qualified reference, previous lot, retained sample, established performance range, or other scientifically justified benchmark.
Record results, deviations, technical review, and the internal decision to accept, conditionally accept, hold, investigate, rework, or reject the lot according to the applicable quality system.
The QC package should be matched to the product. Not every test belongs on every lot, and a research reagent should not be subjected to irrelevant tests simply because they appear on a generic checklist.
Review batch identifiers, critical raw-material lots, manufacturing dates, operators, formulation records, fill records, labels, packaging configuration, and defined production history.
Confirm product identity, reagent set, target configuration, component count, intended concentration, dye/channel assignment, pack size, and other defining attributes.
Where technically appropriate, evaluate nucleic-acid concentration, reagent concentration, pH, conductivity, absorbance, protein concentration, buffer properties, or other measurable formulation characteristics.
Support checks of aliquot volume, vial quantity, reaction count, kit component count, overfill strategy, or other quantity-related manufacturing attributes.
Evaluate amplification behavior, Cq distribution, target detection, control performance, fluorescence channels, efficiency-related behavior, specificity, low-level detection, or other predefined molecular performance criteria.
Evaluate target balance, weak-target sensitivity, channel separation, control competition, nonspecific signal, and lot-specific multiplex behavior in the complete reaction.
Assess expected positive, negative, internal, extraction/process, or other control behavior according to the design and intended research workflow.
Compare the new manufacturing lot with an established reference lot, retained material, benchmark data, or other justified comparator using predefined technical criteria.
Where relevant to the manufacturing stage, confirm defined storage, hold, freeze-thaw, or handling conditions against available supporting data.
Confirm product name, lot identifier, quantity, storage information, component labels, insert revision, RUO language where applicable, and package configuration.
Investigate unexpected QC results, lot shifts, out-of-range observations, labeling errors, fill discrepancies, control failures, or other lot-specific technical questions.
Prepare or support lot-specific worksheets, QC summaries, certificates or technical summaries where appropriate, deviation records, and internal disposition documentation.
IMDNA's framework connects the manufactured lot to its materials, process history, analytical measurements, functional performance, technical review, and final internal disposition.
Acceptance criteria should be defined before testing whenever practical and should be linked to meaningful product attributes. The appropriate tests for a multiplex qPCR reagent are different from those for a buffer, control material, antibody reagent, or kit assembly.
Is this the correct product, formulation, target configuration, component set, and labeled lot?
Are fill volume, reaction count, units, component count, or bulk quantity within the defined manufacturing specification?
Do measurable formulation characteristics meet the expected range where direct testing is appropriate?
Does the reagent generate the expected biological, molecular, fluorescence, enzymatic, or assay response?
Is replicate or run-to-run variation consistent with the product's established QC expectations?
Is target-specific signal preserved without unacceptable negative-control signal, cross-reactivity, or background?
Does the new lot remain technically consistent with a qualified prior lot, reference lot, or established performance window?
Are labels, lot identifiers, storage information, component configuration, records, and packaging correct for the lot?
Molecular reagents require functional evaluation because small changes in oligonucleotide concentration, enzyme performance, buffer chemistry, control material, dye behavior, or raw-material quality can shift Cq values, amplification consistency, sensitivity, specificity, or multiplex balance.
Compare lot-specific target and control Cq behavior against defined reference materials, expected ranges, or qualified lot data.
Confirm that the lot produces the expected target-specific signal with suitable positive materials.
Confirm absence of unacceptable amplification or fluorescence in defined negative or no-template controls.
Where sensitivity is a critical product attribute, include suitable low-concentration materials capable of revealing meaningful lot-related loss of detection performance.
Check that strong targets do not suppress weaker targets and that channel-to-channel behavior remains within the intended multiplex configuration.
Evaluate signal behavior across the relevant dyes and optical channels, including abnormal baseline, low signal, or cross-channel effects.
Confirm that process or internal-amplification controls perform as designed without excessive competition with assay targets.
Where appropriate for the lot and product, use defined negative or related-target materials to confirm that specificity has not materially shifted.
Run candidate and qualified reference lots under controlled conditions to determine whether observed differences are meaningful relative to predefined criteria.
The exact QC panel depends on whether the lot contains primers/probes, master mix, controls, extraction reagents, or an integrated assay kit.
Release criteria should be selected from endpoints that actually demonstrate the product attribute of interest.
A lot comparison should be sensitive enough to detect a meaningful shift. CLSI EP26 addresses user evaluation of new reagent lots and notes that lot-related differences can arise from reagent-component changes, instability, transportation/storage compromise, or calibration issues. EP26 is designed for the receiving medical laboratory—not for a manufacturer to establish product lot variability—but its emphasis on predefined differences, appropriate concentrations, representative samples, and investigation of between-lot differences provides a useful scientific reference for lot-comparison thinking.
| Comparison Question | Examples | IMDNA Support May Include |
|---|---|---|
| Is there a systematic lot shift? | Cq shift, signal shift, calibration shift, concentration difference, bias across samples. | Paired lot testing, summary statistics, difference plots, technical review. |
| Does the new lot retain sensitivity? | Weak targets, low-positive controls, low-concentration reference material. | Low-level challenge study, replicate testing, target-specific comparison. |
| Does multiplex behavior remain stable? | Weak-target suppression, channel imbalance, internal-control competition. | Multi-target challenge, reference-lot comparison, target-by-target review. |
| Is variability increased? | Wider replicate spread, unstable controls, inconsistent fill or signal. | Replicate study, run-to-run review, manufacturing-history investigation. |
| Is an observed difference material? | Difference is statistically visible but may or may not affect the product's technical use. | Compare against predefined product criteria and intended performance requirements. |
Lot-specific QC becomes more informative when the comparator materials are stable enough to distinguish product variation from material variation.
Use well-characterized controls or reference materials with defined expected behavior appropriate to the product.
Where practical, retain representative material from prior qualified lots to support future investigations and comparisons.
For quantitative or sensitivity-dependent products, consider more than one level so lot differences are not assessed only under easy high-signal conditions.
Use relevant negatives to monitor contamination, background, nonspecific amplification, or cross-reactivity.
For multi-component kits, evaluate the components together when performance depends on their interaction rather than testing every component only in isolation.
Record the lot, preparation, storage, and use of QC/reference materials so the QC result can be interpreted in context.
Standard-curve behavior, control recovery, background, signal window, precision, reagent concentration, plate/reagent compatibility, and lot comparison.
Analyte-specific controls, calibration response, bead performance, background, cross-talk, common-dilution behavior, and lot-specific analyte shifts.
Antibody performance, staining intensity, resolution, background, compensation/unmixing behavior, reagent stability, and lot-to-lot comparability.
Functional response, viability, dose response, positive/negative control separation, lot-dependent biological effects, and reagent stability.
pH, conductivity where relevant, appearance, fill volume, extraction recovery, inhibition, downstream assay performance, and stability-related checks.
Component count, lot mapping, labels, inserts, storage configuration, packaging integrity, accessory count, and system-level functional checks where applicable.
QC should not be reduced to a pass/fail checkbox. Unexpected results may identify a material, manufacturing, analytical, documentation, labeling, storage, or testing issue that should be investigated before the lot is supplied.
Review whether the result reflects the lot, QC material, instrument, operator, protocol, analysis setting, or other technical variable.
Examine raw-material lots, preparation, mixing, hold time, fill sequence, storage, operator notes, environmental events, and deviations that may explain the result.
Use scientifically justified repeat testing or orthogonal checks when needed to distinguish random test error from a reproducible lot-related problem.
Develop and test hypotheses around formulation, material, equipment, process, packaging, storage, or analytical causes.
Where appropriate to the product and quality system, provide technical data to support decisions about holding, reprocessing, re-labeling, additional testing, or other corrective work.
Document the responsible organization's decision to accept, hold, rework, or reject the lot based on the defined specification and investigation outcome.
For IVD labeling, FDA requires lot/control numbers that are traceable to production history. More broadly, good lot-level documentation allows product performance to be connected back to raw materials, production, QC data, labels, and any deviations.
Use a unique identifier linked to the manufacturing and QC record.
Link defined critical oligonucleotide, enzyme, antibody, control, buffer, plastic, and other material lots to the product lot.
Document actual preparation, quantities, process parameters, operators, dates, equipment, filling, yields, and deviations.
Capture test methods, instruments, controls, reference materials, results, acceptance criteria, reviewer, and testing date.
Link the applied lot label, storage information, artwork revision, kit configuration, and packaging record to the corresponding lot.
Where appropriate, compile a concise lot-specific technical summary or certificate reflecting the tests actually performed and their defined outcomes.
The term lot release has different meanings depending on product category. FDA's CBER lot-release program is a specific regulatory mechanism for certain licensed biological products in which FDA may review protocols and test samples before a lot is released. That regulatory program should not be confused with IMDNA's internal lot-specific QC and manufacturing disposition of research reagents. On this page, “release testing” means product-specific QC performed to support an internal supply/disposition decision under the applicable manufacturing arrangement.
Requirements depend on product classification and intended use. FDA's QMSR became effective February 2, 2026 for applicable medical-device manufacturers and incorporates ISO 13485:2016 by reference. FDA IVD labeling requirements also require lot/control numbers traceable to production history. These frameworks should not be assumed to apply to every IMDNA RUO product, but they are relevant when a product falls within the regulated-device or IVD framework.
The responsible manufacturer should determine whether QMSR or another regulated quality framework applies to the product and manufacturing role.
Applicable regulated manufacturing may require controlled acceptance activities, records, review, and authorization before distribution under the governing quality system.
Lot/control identifiers and manufacturing history may have specific regulatory requirements depending on product type.
Product specifications, acceptance criteria, manufacturing records, QC records, labels, and disposition should be controlled within the applicable quality system.
OEM and private-label arrangements should clearly identify who approves specifications, performs testing, reviews results, and makes the formal product-disposition decision.
Successful IMDNA lot QC does not itself establish regulatory clearance, approval, certification, registration, or market authorization.
IMDNA provides scientific, technical, manufacturing, lot-specific QC, internal release-testing, assay-performance, documentation, troubleshooting, OEM/private-label, and non-regulatory support based on the needs of each project. Support may include assistance with lot traceability, specification review, identity/configuration checks, concentration or formulation measurements, fill-volume checks, functional qPCR/RT-qPCR QC, controls, multiplex performance, lot-to-lot comparison, packaging/label verification, deviation investigation, QC summaries, and internal lot-disposition support.
Where appropriate, IMDNA may manufacture, test, assemble, package, or supply research-use products and may perform predefined lot-level QC under the applicable manufacturing arrangement. The exact test panel and acceptance criteria should be matched to the product rather than inferred from a generic list.
IMDNA's use of the term “release testing” on this page refers to internal manufacturing QC and lot-disposition support. It does not mean FDA CBER lot release, governmental lot certification, regulatory approval, accreditation, or market authorization.
IMDNA is not a regulatory, licensing, accreditation, certification, legal, governmental, or inspecting authority. IMDNA does not independently determine that a product satisfies every applicable regulatory requirement and does not guarantee that a lot will be accepted by a customer, laboratory, regulator, accreditation body, or other third party.
The responsible product owner or manufacturer remains responsible for determining the product's regulatory classification and intended use; approving specifications and lot acceptance criteria; determining which tests are required; assigning authorized lot-disposition responsibilities; controlling applicable manufacturing and quality records; and obtaining any required registration, listing, licensing, certification, clearance, approval, or other market authorization.
References to governmental, regulatory, standards-development, scientific, or professional organizations are provided for general informational purposes only and do not imply endorsement, approval, affiliation, certification, or sponsorship of IMDNA or its services.
The following resources support the general concepts of lot traceability, reagent-lot comparison, lot-level acceptance, quality-system control, and product-specific lot release. Their formal applicability depends on the product category and intended use.
Tell IMDNA about your product type, formulation, critical raw materials, target assay, reference lot, controls, expected performance, QC endpoints, fill format, packaging, storage conditions, lot size, and technical acceptance criteria. Our scientific and manufacturing team can help organize a lot-specific QC program covering traceability, functional testing, qPCR/RT-qPCR performance, multiplex behavior, lot comparison, packaging checks, deviation investigation, documentation, and internal lot-disposition support.